Ridgeline Therapeutics, Inc.
Houston, TX
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Website
- ridgelinetherapeutics.com
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
About the company
Ridgeline Therapeutics LLC is a Houston-based biotechnology company focused on developing innovative small molecule therapeutics targeting muscle health, aging, and metabolic conditions. Registered in SAM.gov since 2012, the company specializes in research and development of novel pharmaceutical interventions, with a particular emphasis on compounds that address muscle degeneration, obesity, and age-related physiological challenges. The company's primary research platform centers on developing small molecule drugs that inhibit nicotinamide N-methyltransferase (NNMT), an enzyme critical for cellular energy metabolism and muscle stem cell activation.
The company has secured multiple federal grant awards from agencies like the National Institute on Aging and the Defense Health Agency, totaling approximately $2.48 million in project grants between 2021 and 2025. These grants support preclinical research on compounds such as RT-002 and RT-001, which aim to prevent muscle loss, enhance weight loss, improve muscle strength, and address conditions like osteoarthritis and disuse-induced muscle atrophy. Specific research objectives include developing therapeutic interventions for older adults, evaluating drug efficacy in diet-induced obesity mouse models, and creating treatments to accelerate muscle regeneration and recovery from injuries. The grants span various research domains, including musculoskeletal injury recovery, muscle stem cell activation, obesity treatment, and potential interventions for age-related muscle degeneration, with a focus on translating preclinical findings into potential clinical treatments for military and civilian populations.
Quick answers
Is Ridgeline Therapeutics, Inc. registered in SAM.gov?
Yes. Ridgeline Therapeutics, Inc.'s SAM.gov registration is active through May 5, 2027.
What is Ridgeline Therapeutics, Inc.'s CAGE code?
Ridgeline Therapeutics, Inc.'s CAGE code is 6PN60, and its Unique Entity ID (UEI) is KM9RHDLMHTN5.
What is Ridgeline Therapeutics, Inc.'s most recent federal award?
Ridgeline Therapeutics, Inc.'s most recent federal grant award is Cardiovascular safety and scalable manufacturing for investigational new drug filing of a novel oral drug to accelerate… (R44AG102216), from National Institute on Aging (NIH), on September 17, 2026.
On GovTribe
See Ridgeline Therapeutics, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors